Novo Nordisk Shares Face Mounting Pressure as Analyst Warns of Further Declines

A leading financial institution has issued a stark warning for investors in Novo Nordisk, suggesting the Danish pharmaceutical giant’s stock may continue its precipitous fall. Despite a year-to-date loss of approximately 50% in market capitalization, Jefferies analysts believe the bottom has not yet been reached.

A Grim Forecast from Wall Street

In a move that dampened market sentiment, Jefferies resumed coverage of Novo Nordisk with a stark “Underperform” rating. Analyst Michael Leuchten set a price target of 270 Danish Krone (DKK), implying a potential further decline of about 14% from current trading levels. The firm’s analysis points to two core concerns: the continued absence of a valuation floor despite the year’s severe losses and looming structural threats.

While potential price reductions in the United States might stimulate short-term demand, Jefferies highlights the persistent danger from growing generic competition and upcoming patent expirations. This cloud hangs over the market leader in GLP-1 medications, used for diabetes and weight management.

Management Counters with Strategy and Science

In response to market pressures, Novo Nordisk’s executives are emphasizing strategic continuity and innovation. Chief Strategy Officer Dorethe Nielsen confirmed the company would maintain its climate goals despite announced cost-saving measures.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

The firm’s financial chief, Karsten Munk Knudsen, recently framed innovation as the “ultimate defense” against competitive pressure from rivals like Eli Lilly. The company’s pipeline, particularly the drug candidate Amycretin, is central to this strategy. Early trial data indicates promising weight loss results that could surpass existing treatments. Furthermore, a key patent shield protects its crucial U.S. market—responsible for half of its revenue—until the early 2030s.

A Market Divided on Outlook

The current investment landscape presents a paradox. Jefferies’ bearish stance contrasts sharply with the broader analyst consensus, which remains optimistic. The average price target among market experts sits above 400 DKK, representing a significant gap compared to both the current share price and Jefferies’ forecast.

From a fundamental perspective, the stock appears historically inexpensive, trading at an estimated 2025 price-to-earnings ratio of 13.7. However, the steep year-to-date decline of over 50% underscores a profound erosion of market confidence. Investors are now closely watching to see if current support levels will hold or if bearish sentiment will continue to dictate the stock’s trajectory.